Advertisement
Singapore markets closed
  • Straits Times Index

    3,178.36
    +6.43 (+0.20%)
     
  • S&P 500

    5,149.42
    +32.33 (+0.63%)
     
  • Dow

    38,790.43
    +75.63 (+0.20%)
     
  • Nasdaq

    16,103.45
    +130.25 (+0.82%)
     
  • Bitcoin USD

    63,444.20
    -4,343.02 (-6.41%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,716.59
    -5.96 (-0.08%)
     
  • Gold

    2,156.00
    -8.30 (-0.38%)
     
  • Crude Oil

    82.68
    -0.04 (-0.05%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • Nikkei

    40,003.60
    +263.20 (+0.66%)
     
  • Hang Seng

    16,529.48
    -207.62 (-1.24%)
     
  • FTSE Bursa Malaysia

    1,544.96
    -8.68 (-0.56%)
     
  • Jakarta Composite Index

    7,336.75
    +34.30 (+0.47%)
     
  • PSE Index

    6,848.43
    -4.86 (-0.07%)
     

A Look at Intercept Pharmaceuticals’ Cash Flows

A Look at Intercept Pharmaceuticals’ Cash Flows

Intercept Pharmaceuticals (ICPT) spent $265.4 million on operating activities in fiscal 2017 compared with $342.4 million in fiscal 2016. In fiscal 2017, Intercept Pharmaceuticals generated $2.8 million from financing activities, which were mainly from the exercise of options to purchase common stock. On April 5, 2018, Intercept Pharmaceuticals announced pricing of the upsized $250 million public offering of its common stock with a concurrent private placement of 1.5 million of its common shares.